These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23289432)

  • 1. Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: results from OBSTACLE Hypoglycemia Study.
    Kalra S; Deepak MC; Narang P; Singh V; Uvaraj MG; Agrawal N
    Diabetes Technol Ther; 2013 Feb; 15(2):129-35. PubMed ID: 23289432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between measures of hypoglycemia and glycemic improvement in sulfonylurea treated patients with type 2 diabetes in India: results from the OBSTACLE hypoglycemia study.
    Kalra S; Deepak MC; Narang P; Singh V; Maheshwari A
    J Postgrad Med; 2014; 60(2):151-5. PubMed ID: 24823514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.
    Laires PA; Tang J; Fan CP; Li Z; Qiu Y; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):213-220. PubMed ID: 27345181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
    Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
    J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
    Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
    Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study.
    Matsuoka A; Hirota Y; Takeda A; Kishi M; Hashimoto N; Ohara T; Higo S; Yamada H; Nakamura T; Hamaguchi T; Takeuchi T; Nakagawa Y; Okada Y; Sakaguchi K; Ogawa W
    J Diabetes Investig; 2020 Mar; 11(2):417-425. PubMed ID: 31461223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward.
    Wojszel ZB; Kasiukiewicz A
    BMC Geriatr; 2019 Sep; 19(1):242. PubMed ID: 31477024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
    Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
    Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
    Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
    Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
    Basit A; Riaz M; Fawwad A
    Vasc Health Risk Manag; 2012; 8():463-72. PubMed ID: 23028231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing potential glycemic overtreatment in persons at hypoglycemic risk.
    Tseng CL; Soroka O; Maney M; Aron DC; Pogach LM
    JAMA Intern Med; 2014 Feb; 174(2):259-68. PubMed ID: 24322626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial.
    ORIGIN Trial Investigators
    Diabetes Care; 2015 Jan; 38(1):22-8. PubMed ID: 25352653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.